Literature DB >> 24114776

Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence.

Pasquale Santangeli1, Luigi Di Biase, Sakis Themistoclakis, Antonio Raviele, Robert A Schweikert, Dhanunjaya Lakkireddy, Prasant Mohanty, Rong Bai, Sanghamitra Mohanty, Agnes Pump, Salwa Beheiry, Richard Hongo, Javier E Sanchez, G Joseph Gallinghouse, Rodney Horton, Antonio Dello Russo, Michela Casella, Gaetano Fassini, Claude S Elayi, J David Burkhardt, Claudio Tondo, Andrea Natale.   

Abstract

BACKGROUND: Pulmonary vein (PV) antrum isolation in patients with hypertrophic cardiomyopathy and atrial fibrillation (AF) has been reported to have satisfactory results at the mid- and short-term follow-up. We determined the outcomes at the long-term follow-up of PV antrum isolation in these patients. METHODS AND
RESULTS: We enrolled 43 patients with hypertrophic cardiomyopathy and AF (28% paroxysmal AF). PV antrum isolation (paroxysmal AF) and posterior wall isolation with complex fractionated atrial electrogram ablation (persistent and longstanding persistent AF) were the end points at the time of the index procedure and for repeat procedures during the first year of follow-up. In case of recurrent arrhythmia >1 year, high-dose isoproterenol challenge was used to disclose non-PV trigger sites. During the first year, the success rate reached 91% (mean of 1.6 procedures). After a median follow-up of 42 months (range, 38-48 months), 49% of the patients remained free from AF/atrial tachycardia. All patients underwent an additional procedure. PV antrum and posterior wall remained isolated in 82% of the cases, and extra-PV triggers were documented in all patients and targeted for ablation. After a median follow-up of 15 months (range, 8-19 months) subsequent to the last procedure, 94% of the patients remained free from AF/atrial tachycardia off antiarrhythmic drugs.
CONCLUSIONS: PV isolation in patients with hypertrophic cardiomyopathy is feasible and safe, although is not effective in preventing late (≥1 year) AF recurrences in ≈50% of patients. Non-PV triggers seem to be responsible of late recurrences, which supports the appropriateness of a more extensive ablation beyond PV isolation to improve the long-term arrhythmia-free survival.

Entities:  

Keywords:  atrial fibrillation; cardiomyopathies; cardiomyopathy, hypertrophic; catheter ablation

Mesh:

Year:  2013        PMID: 24114776     DOI: 10.1161/CIRCEP.113.000339

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  12 in total

Review 1.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management.

Authors:  Monica Patten; Simon Pecha; Ali Aydin
Journal:  J Atr Fibrillation       Date:  2018-02-28

Review 2.  Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.

Authors:  Lohit Garg; Manasvi Gupta; Syed Rafay Ali Sabzwari; Sahil Agrawal; Manyoo Agarwal; Talha Nazir; Jeffrey Gordon; Babak Bozorgnia; Matthew W Martinez
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

Review 3.  Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy patients: a systematic review.

Authors:  Hakeem S K Ha; Nelson Wang; Sophia Wong; Steven Phan; Jace Liao; Narendra Kumar; Pierre Qian; Tristan D Yan; Kevin Phan
Journal:  J Interv Card Electrophysiol       Date:  2015-08-25       Impact factor: 1.900

Review 4.  Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline.

Authors:  Ariane Fraiche; Andrew Wang
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

5.  Impact of Cryoballoon Ablation in Hypertrophic Cardiomyopathy-related Heart Failure due to Paroxysmal Atrial Fibrillation. A Comparative Case Series.

Authors:  Petra Maagh; Gunnar Plehn; Arnd Christoph; Ahmet Oernek; Axel Meissner
Journal:  Int J Med Sci       Date:  2016-08-01       Impact factor: 3.738

Review 6.  Hypertrophic cardiomyopathy.

Authors:  Murillo de Oliveira Antunes; Thiago Luis Scudeler
Journal:  Int J Cardiol Heart Vasc       Date:  2020-03-25

7.  Utilization and Complications of Catheter Ablation for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.

Authors:  Guy Rozen; Gabby Elbaz-Greener; Ibrahim Marai; Nizar Andria; Seyed Mohammadreza Hosseini; Yitschak Biton; E Kevin Heist; Jeremy N Ruskin; Yulia Gavrilov; Shemy Carasso; Diab Ghanim; Offer Amir
Journal:  J Am Heart Assoc       Date:  2020-06-23       Impact factor: 5.501

8.  Ablation of Atrial Fibrillation in Hypertrophic Cardiomyopathy: Semper Discere (Always Learning).

Authors:  N A Mark Estes; Timothy C Wong
Journal:  J Am Heart Assoc       Date:  2021-01-17       Impact factor: 5.501

9.  Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy: Treatment Strategy, Characteristics of Consecutive Atrial Tachycardia and Long-Term Outcome.

Authors:  Leon Dinshaw; Paula Münkler; Benjamin Schäffer; Niklas Klatt; Christiane Jungen; Jannis Dickow; Annika Tamenang; Ruben Schleberger; Simon Pecha; Hans Pinnschmidt; Monica Patten; Hermann Reichenspurner; Stephan Willems; Christian Meyer
Journal:  J Am Heart Assoc       Date:  2021-01-17       Impact factor: 5.501

10.  Characteristics of left atrial remodeling in patients with atrial fibrillation and hypertrophic cardiomyopathy in comparison to patients without hypertrophy.

Authors:  Sotirios Nedios; Borislav Dinov; Timm Seewöster; Frank Lindemann; Sergio Richter; Arash Arya; Nikolaos Dagres; Daniela Husser; Andreas Bollmann; Gerhard Hindricks; Andreas Müssigbrodt
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.